Biogen

Information

Name

Biogen

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

http://www.biogen.uk.com

Address

Maidenhead

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Biogen
Sign up free

Contracts awarded to Biogen

The contracts that Biogen have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 3 months ago

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

roject title: CM/PHS/24/5707 NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024 Period of framework: 1 August 2024 to 31 July 2025. with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

£416,830,570 Bids close: 7 months ago
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 7 months ago
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months

£74
Award

Published 8 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

£580,156,000 Bids close: 1 year ago
Award

Published 9 months ago

CM/PHR/23/5701- NHS National Framework for Natalizumab-February 2024

NHS National Framework for Natalizumab - February 2024 Offer reference number: CM/PHR/23/5701 Period of framework: 1 February 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£63,746,000 Bids close: 11 months ago

Biogen

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Biogen

NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

CM/PHR/23/5701- NHS National Framework for Natalizumab-February 2024

Contacts

Statistics (1 Year)